PDF(Pubmed)
Abstract：
UNASSIGNED: Lenvatinib or Sorafenib combined with programmed cell death protein-1 (PD-1) inhibitor as recommend treatment of advanced hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM). We aimed to compared the prognosis of Lenvatinib plus PD-1 inhibitor (Len+PD-1) versus Sorafenib plus PD-1 (Sora+PD-1) as an initial therapy for HCC with EHM.
UNASSIGNED: Incorporating a sum of 229 HCC patients with EHM were encompassed within this study, with 127 in the Sora+PD-1 group and 102 in the Len+PD-1 group. Through propensity score matching (PSM), we compared overall survival (OS), progression-free survival (PFS), and patient safety between these two groups.
UNASSIGNED: The median OS were 13.0 months and 14.2 months in the Sora+PD-1 group and Len+PD-1 group. The 6-, 12-, and 24-month OS rates were 92.9%, 58.9% and 5.6% in Sora+PD-1 group and 93.1%, 61.8% and 22.6% in Len+PD-1 group, respectively. The Len+PD-1 group had obviously better OS than the Sora+PD-1 group (P = 0.002). The 3-, 6-, and 12-month PFS rates were 76.4%, 27.6% and 1.6% in Sora+PD-1 group and 86.2%, 50.5% and 12.2% in Len+PD-1 group, respectively. Compared with Sora+PD-1 group, the Len+PD-1 group had obviously better PFS (P < 0.001). Analysis within subgroups showed that OS was significant in patients receiving TACE in Len+PD-1 group than Sora+PD-1 group (p = 0.003).
UNASSIGNED: Len+PD-1 group had longer OS and PFS than Sora+PD-1 group for patient with EHM. In addition, OS in patients received TACE was improved with Len+PD-1 treatment. For patients without TACE, there was no significance between Sora+PD-1 and Len+PD-1 groups.
UNASSIGNED: Incorporating a sum of 229 HCC patients with EHM were encompassed within this study, with 127 in the Sora+PD-1 group and 102 in the Len+PD-1 group. Through propensity score matching (PSM), we compared overall survival (OS), progression-free survival (PFS), and patient safety between these two groups.
UNASSIGNED: The median OS were 13.0 months and 14.2 months in the Sora+PD-1 group and Len+PD-1 group. The 6-, 12-, and 24-month OS rates were 92.9%, 58.9% and 5.6% in Sora+PD-1 group and 93.1%, 61.8% and 22.6% in Len+PD-1 group, respectively. The Len+PD-1 group had obviously better OS than the Sora+PD-1 group (P = 0.002). The 3-, 6-, and 12-month PFS rates were 76.4%, 27.6% and 1.6% in Sora+PD-1 group and 86.2%, 50.5% and 12.2% in Len+PD-1 group, respectively. Compared with Sora+PD-1 group, the Len+PD-1 group had obviously better PFS (P < 0.001). Analysis within subgroups showed that OS was significant in patients receiving TACE in Len+PD-1 group than Sora+PD-1 group (p = 0.003).
UNASSIGNED: Len+PD-1 group had longer OS and PFS than Sora+PD-1 group for patient with EHM. In addition, OS in patients received TACE was improved with Len+PD-1 treatment. For patients without TACE, there was no significance between Sora+PD-1 and Len+PD-1 groups.
摘要：
■Lenvatinib或索拉非尼联合程序性细胞死亡蛋白-1（PD-1）抑制剂作为晚期肝细胞癌（HCC）肝外转移（EHM）的推荐治疗。我们旨在比较Lenvatinib加PD-1抑制剂（LenPD-1）与索拉非尼加PD-1（SoraPD-1）作为EHMHCC的初始治疗的预后。
■纳入了229例EHMHCC患者的总和，Sora+PD-1组127人，Len+PD-1组102人。通过倾向得分匹配(PSM)，我们比较了总生存期(OS)，无进展生存期（PFS），这两组之间的患者安全。
■Sora+PD-1组和Len+PD-1组的中位OS分别为13.0个月和14.2个月。6-，12-，24个月OS率为92.9%，Sora+PD-1组的58.9%和5.6%，93.1%，Len+PD-1组分别为61.8%和22.6%，分别。Len+PD-1组的OS明显优于Sora+PD-1组(P=0.002)。3、6-，12个月的PFS率为76.4%，Sora+PD-1组分别为27.6%和1.6%，86.2%，Len+PD-1组分别为50.5%和12.2%,分别。与Sora+PD-1组相比，Len+PD-1组PFS明显优于对照组(P<0.001)。亚组内的分析表明，LenPD-1组接受TACE的患者的OS比SoraPD-1组显着（p=0.003）。
■对于EHM患者，Len+PD-1组比Sora+PD-1组具有更长的OS和PFS。此外,Len+PD-1治疗可改善接受TACE的患者的OS。对于没有TACE的患者，Sora+PD-1组和Len+PD-1组之间无显著性差异.
■纳入了229例EHMHCC患者的总和，Sora+PD-1组127人，Len+PD-1组102人。通过倾向得分匹配(PSM)，我们比较了总生存期(OS)，无进展生存期（PFS），这两组之间的患者安全。
■Sora+PD-1组和Len+PD-1组的中位OS分别为13.0个月和14.2个月。6-，12-，24个月OS率为92.9%，Sora+PD-1组的58.9%和5.6%，93.1%，Len+PD-1组分别为61.8%和22.6%，分别。Len+PD-1组的OS明显优于Sora+PD-1组(P=0.002)。3、6-，12个月的PFS率为76.4%，Sora+PD-1组分别为27.6%和1.6%，86.2%，Len+PD-1组分别为50.5%和12.2%,分别。与Sora+PD-1组相比，Len+PD-1组PFS明显优于对照组(P<0.001)。亚组内的分析表明，LenPD-1组接受TACE的患者的OS比SoraPD-1组显着（p=0.003）。
■对于EHM患者，Len+PD-1组比Sora+PD-1组具有更长的OS和PFS。此外,Len+PD-1治疗可改善接受TACE的患者的OS。对于没有TACE的患者，Sora+PD-1组和Len+PD-1组之间无显著性差异.
